Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.
In a Dec. 3, 2019 press release, Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.
Through the integration of the knockout cell models into the Cell Atlas program, it is hoped that understanding of genetic drivers of disease will be advanced. Additionally, knockout cell models offer a possibility of enhanced validation of antibodies based on genetic strategies as a result of the absence of the targeting protein, which correlates with a loss of signal for specific antibodies.
“Horizon has over a decade of experience in gene editing, and a well-established reputation for providing CRISPR-edited knockout cell models,” said Professor Emma Lundberg, who is responsible for the HPA Cell Atlas program, in the press release. “We have previously used Horizon’s cell lines in our high throughput imaging processes with great success. Using a validated gene-edited cell line where all cell models have the same background will be key to maximizing efficiency and achieving data reproducibility.”
Terry Pizzie, CEO, Horizon Discovery, added, “Having contributed to several thousands of publications in the field of human biology and disease, the HPA is a highly regarded knowledge provider and an expert in the field of molecular mechanisms of the human cell. We are delighted to partner with HPA to provide the robust research tools required to extend their database, and we are proud to be contributing to the expansion of this renowned open access resource for both academia and industry.”
Source: Horizon
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.